Is Tazemetostat included in medical insurance?

Tazemetostat, branded under the brand name Tazverik, is a drug used to treat people ages 16 and older with metastatic (when cancer cells have spread to other parts of the body) or localized cancer. Medication for adults and teenagers with epithelioid sarcoma that is not suitable for complete resection (surgery to remove all tissue, structures, or organs) (when the cancer has grown beyond the organ where it started, but has not spread to other parts of the body). Tazerestat is an anticancer drug that acts as a potent and selective EZH2 inhibitor that blocks the activity of EZH2 methyltransferase, which may help prevent cancer cell growth.

Tazerestat is an oral, small molecule selective and competitive inhibitor of S-adenosylmethionine (SAM) of histone methyltransferase EZH2 with potential anti-tumor activity. After oral administration, tazerestat selectively inhibits the activity of wild-type and mutantEZH2. Inhibition of EZH2 specifically prevents methylation of histone H3 lysine 27 (H3K27) . This reduction in histone methylation alters gene expression patterns associated with cancer pathways and results in reduced tumor cell proliferation in EZH2 mutant cancer cells.

The original drug of tazerestat is not yet available in the domestic market and is therefore not included in medical insurance. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.